Naperville, IL -- (SBWire) -- 01/02/2015 --Reportstack, provider of premium market research reports announces the addition of Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023 market report to its offering

Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023

Summary

The publisher has released its new PharmaPoint Drug Evaluation report, Vectibix (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Amgen/Takedas EGFR antagonist Vectibix (panitumumab) was approved in the US in 2006 as a monotherapy for chemotherapy-refractory, EGFR-expressing, KRAS wild-type metastatic CRC. EU approval followed in 2007, where the agent is also indicated as a treatment for chemotherapy-refractory KRAS wild-type CRC patients, however, EGFR-expression is not specified. Additionally in the EU, the antibody is approved in combination with FOLFOX in the first-line setting, and with FOLFIRI in the second-line setting after progression on a 5-FU regimen. In April 2014, the EU label for Vectibix was updated to specify RAS wild-type disease rather than KRAS.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Vectibix including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Vectibix for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Vectibix performance

- Obtain sales forecast for Vectibix from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Complete report is available
http://www.reportstack.com/product/188955/vectibix-colorectal-cancer-forecast-and-market-analysis-to-2023.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604